Skip to main content
The FDA has extended the approval for the Human Papillomavirus Quadrivalent Recombinant Vaccine to include the prevention of vaginal and vulvar cancer. The vaccine, originally approved in 2006, is already approved for the prevention of cervical cancer and genital warts.

Human Papillomavirus Quadrivalent Recombinant Vaccine (Gardasil®)